|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/08/22 Celldex Therapeutics, Inc. 10-Q 6/30/22 60:5.5M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.26M
2: EX-10.3 Material Contract HTML 29K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 22K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 22K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
11: R1 Document and Entity Information HTML 73K
12: R2 Condensed Consolidated Balance Sheets HTML 113K
13: R3 Condensed Consolidated Balance Sheets HTML 35K
(Parenthetical)
14: R4 Condensed Consolidated Statements of Operations HTML 86K
and Comprehensive Loss
15: R5 Condensed Consolidated Statements of Cash Flow HTML 80K
16: R6 Basis of Presentation HTML 25K
17: R7 Significant Accounting Policies HTML 21K
18: R8 Fair Value Measurements HTML 96K
19: R9 Marketable Securities HTML 110K
20: R10 Intangible Assets HTML 20K
21: R11 Other Long-Term Liabilities HTML 36K
22: R12 Stockholders' Equity HTML 153K
23: R13 Stock-Based Compensation HTML 81K
24: R14 Accumulated Other Comprehensive Income HTML 40K
25: R15 Revenue HTML 23K
26: R16 Income Taxes HTML 22K
27: R17 Net Loss Per Share HTML 27K
28: R18 Kolltan Acquisition HTML 28K
29: R19 Significant Accounting Policies (Policies) HTML 20K
30: R20 Fair Value Measurements (Tables) HTML 95K
31: R21 Marketable Securities (Tables) HTML 108K
32: R22 Other Long-Term Liabilities (Tables) HTML 35K
33: R23 Stockholders' Equity (Tables) HTML 148K
34: R24 Stock-Based Compensation (Tables) HTML 84K
35: R25 Accumulated Other Comprehensive Income (Tables) HTML 39K
36: R26 Net Loss Per Share (Tables) HTML 26K
37: R27 Basis of Presentation (Details) HTML 30K
38: R28 Fair Value Measurements (Details) HTML 45K
39: R29 Fair Value Measurements - Contingent Consideration HTML 26K
Liabilities (Details)
40: R30 Fair Value Measurements - Additional information HTML 29K
(Details)
41: R31 Marketable Securities (Details) HTML 58K
42: R32 Marketable Securities - Additional Information HTML 21K
(Details)
43: R33 Intangible Assets (Details) HTML 19K
44: R34 Other Long-Term Liabilities (Details) HTML 32K
45: R35 Other Long-Term Liabilities- New Jersey tax HTML 26K
benefits (Details)
46: R36 Stockholders' Equity (Details) HTML 60K
47: R37 Stock-Based Compensation - Stock Option Activity HTML 64K
(Details)
48: R38 Stock-Based Compensation - Employee Stock Option HTML 29K
and Incentive Plan Activity Additional Information
(Details)
49: R39 Stock-Based Compensation - Expenses (Details) HTML 24K
50: R40 Stock-Based Compensation - Valuation (Details) HTML 32K
51: R41 Accumulated Other Comprehensive Income (Details) HTML 38K
52: R42 Revenue (Details) HTML 38K
53: R43 Income Taxes (Details) HTML 19K
54: R44 Net Loss Per Share (Details) HTML 22K
55: R45 Kolltan Acquisition (Details) HTML 39K
58: XML IDEA XML File -- Filing Summary XML 103K
56: XML XBRL Instance -- cldx-20220630x10q_htm XML 1.45M
57: EXCEL IDEA Workbook of Financial Reports XLSX 82K
7: EX-101.CAL XBRL Calculations -- cldx-20220630_cal XML 114K
8: EX-101.DEF XBRL Definitions -- cldx-20220630_def XML 327K
9: EX-101.LAB XBRL Labels -- cldx-20220630_lab XML 756K
10: EX-101.PRE XBRL Presentations -- cldx-20220630_pre XML 529K
6: EX-101.SCH XBRL Schema -- cldx-20220630 XSD 94K
59: JSON XBRL Instance as JSON Data -- MetaLinks 248± 387K
60: ZIP XBRL Zipped Folder -- 0001104659-22-087222-xbrl Zip 221K
Exhibit 32.1
SECTION 1350 CERTIFICATIONS
Pursuant to 18 U.S.C. §1350 as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, the undersigned officers of Celldex Therapeutics, Inc. (the “Company”) hereby certify that to their knowledge and in their respective capacities that the Company’s quarterly report on Form 10-Q to which this certification is attached (the “Report”), fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 8, 2022 | By: | |
| Name: | |
| Title: | President and Chief Executive Officer |
| | |
Date: August 8, 2022 | By: | /s/ SAM MARTIN |
| Name: | |
| Title: | Senior Vice President and Chief Financial Officer |
This certification shall not be deemed “filed” for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Celldex Therapeutics, Inc. and will be retained by Celldex Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/8/22 | 8-K | ||
| For Period end: | 6/30/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/26/24 Celldex Therapeutics, Inc. 10-K 12/31/23 87:8.5M Toppan Merrill/FA2 2/28/23 Celldex Therapeutics, Inc. 10-K 12/31/22 85:8.1M Toppan Merrill/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/18/22 Celldex Therapeutics, Inc. 8-K:1,9 7/15/22 11:257K Toppan Merrill/FA 6/23/22 Celldex Therapeutics, Inc. 8-K:1,2,9 6/20/22 11:225K Toppan Merrill/FA |